Form 4: scPharmaceuticals CFO Rachael Nokes Reports Stock and Option Awards
SEC Form 4 Filing
Rachael Nokes, CFO and Treasurer of scPharmaceuticals Inc., reports the acquisition of restricted stock units and stock options.
Summary
- On February 11, 2025, Rachael Nokes, CFO and Treasurer of scPharmaceuticals Inc., reported transactions related to the company's stock.
- Nokes acquired 88,445 shares of common stock through a restricted stock unit (RSU) award.
- These RSUs vest in four equal installments on each anniversary of January 1, 2025, becoming fully vested by January 1, 2029.
- Nokes also acquired options to purchase 132,670 shares of common stock at an exercise price of $3.34.
- These options vest over a four-year period, starting with 25% on January 1, 2026, and the remainder in 36 equal monthly installments, fully vesting by January 1, 2029.
- Following these transactions, Nokes directly owns 156,061 shares of scPharmaceuticals Inc. common stock and options for 132,670 shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The filing reflects standard executive compensation practices, which are generally viewed as a positive incentive for management.
Positives
- The grant of RSUs and stock options to the CFO aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.
Future Outlook
The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules for the RSUs and stock options extend to January 1, 2029.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.
Comparison to Industry Standards
- Stock option and RSU grants are a common form of executive compensation in the pharmaceutical industry, used to align management's interests with those of shareholders.
- Vesting schedules of four years are typical for such grants, similar to practices at companies like Amgen, Biogen, and Vertex Pharmaceuticals.
Stakeholder Impact
- Shareholders may view the RSU and stock option grants as a positive incentive for the CFO to drive company performance.
- Employees may see the grants as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 02/11/2025 | Date of transaction: Rachael Nokes acquired RSUs and stock options. |
| 02/12/2025 | Date of signature on the Form 4 filing. |
| 01/01/2025 | First vesting date for 25% of the RSU shares. |
| 01/01/2026 | First vesting date for 25% of the option shares. |
| 01/01/2029 | Date when all RSUs and option shares will be fully vested. |
| 02/11/2035 | Expiration date of the stock options. |
Keywords
scPharmaceuticals, Rachael Nokes, Form 4, stock options, RSU, restricted stock units, beneficial ownership, CFO, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.